JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
Journal of Clinical Oncology (JCO) Podcast
Release Date: 06/01/2026
Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
Journal of Clinical Oncology (JCO) Podcast
Guests Dr. Elise Park, Dr. Jamie Ostrov and host Dr. Davide Soldato discuss JCO article "" and their groundbreaking trial on virtual tobacco cessation treatment for cancer patients in community settings. LINK TO FULL TRANSCRIPT
info_outline
Phase 2 Study of Multi-Cancer Detection from Breath Samples
Journal of Clinical Oncology (JCO) Podcast
Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "" and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings, the Bayesian modeling integration, and future prospects for scalable, non-invasive cancer screening methods.
info_outline
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "."
info_outline
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
Journal of Clinical Oncology (JCO) Podcast
JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O’Reilly discuss the ASCO 2026 Simultaneous Publication paper "."
info_outline
JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "."
info_outline
JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Umang Swami discuss the ASCO 2026 Simultaneous Publication paper "."
info_outline
JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC
Journal of Clinical Oncology (JCO) Podcast
JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Andrea Necchi discuss the ASCO 2026 Simultaneous Publication paper "."
info_outline
Adjuvant Durvalumab and the Future of Early-Stage NSCLC
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, "" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment.
info_outline
JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer
Journal of Clinical Oncology (JCO) Podcast
Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study."
info_outline
Infections in Two Diet Strategies in HSCT and Leukemia Patients
Journal of Clinical Oncology (JCO) Podcast
Guest Dr. John Wingard and host Dr. Davide Soldato discuss JCO article, "," the reason behind the trial, its design, methodology, results, and the implications for future dietary approaches in hematology.
info_outlineJCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study."